Reading DCGO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track DCGO free→Reading DCGO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track DCGO free→NASDAQHealth CareMedical Care FacilitiesSnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been fairly steady, and it has a capital-friendly stance. Risk is high, and the sector backdrop is a headwind, with performance compared to sector peers being typical. Peer multiples imply a price about 80% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples, but recent financials are weak. This analysis is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $0.58. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $0.58 DCGO trades at 0× p/s, below its 1× p/s peer median. Our $2.92 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 80% below a flat-multiple fair value, below our forecast of about -20%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted -0.10x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
6 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.01 → $-0.15 (-1583.3% / 30d). 0 raised, 0 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d. 40% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$359.
How much price usually moves either way.
On a bad day, this stock has moved -$673.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,995.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If the health care sector's growth picks up, it could benefit DocGo. This would improve its competitive position.
Confirms:Health care sector revenue growth is speeding up toward 10% or more.
Disproves:Sector growth keeps slowing down below current levels.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for DCGO yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 11, 2026, DocGo Inc. (the “Company”) issued a press release announcing the Company’s earnings results for the quarter ended March 31, 2026 (the “Press Release”). The Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”). As previously announced, the Company will also hold a conference call and webcast at 5:00 p.m. Eastern Time on May 11, 2026 to discuss its earnings results for the quarter ended Marc…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Facilities.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
DCGO DocGo, Inc. | Typical Show detailsSector percentile: 37 of 100 | inexpensive | high |
HCA HCA Healthcare | Above typical Show detailsSector percentile: 82 of 100 | fair | moderate |
THC Tenet Health | Above typical Show detailsSector percentile: 86 of 100 | fair | elevated |
EHC Encompass Health | Above typical Show detailsSector percentile: 97 of 100 | full | moderate |
UHS Universal Health Services | Above typical Show detailsSector percentile: 92 of 100 | inexpensive | elevated |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management has increased the full-year 2026 revenue guidance to $300-$315 million.
Management aims to reduce the adjusted EBITDA loss for full-year 2026 to $5-$10 million.
Management is focused on addressing the Nasdaq listing compliance issue due to the stock's closing bid price.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 17, 2026, Stephen K. Klasko, MD notified DocGo Inc. (the “Company”) of his decision to step down as a member of the Board of Directors (the “Board”) and his other Board and committee positions because he accepted a new significant healthcare leadership role, effective as of the conclusion of the Company’s 2026 Annual Meeting of Stockholder…
Results of Operations and Financial Condition. On March 16, 2026, DocGo Inc. (the “Company”) issued a press release announcing the Company’s earnings results for the quarter and year ended December 31, 2025 (the “Press Release”). The Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”). As previously announced, the Company will also hold a conference call and webcast at 5:00 p.m. Eastern Time on March 16, 2026 to discuss its earnings results for the qu…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 26, 2026, DocGo Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (“Common Stock”), from December 9, 2025 to January 23, 2026, the Company is not currently in com…
Regulation FD Disclosure. On December 12, 2025, the Board of Directors of DocGo Inc. (the “Company”) approved an extension of the expiration date of the Company’s current share repurchase program (“Repurchase Program”) from December 31, 2025 to June 30, 2026. As previously disclosed, pursuant to the Repurchase Program, the Company may purchase up to $26 million in shares of the Company’s common stock. Other than the extension of the program’s expiration date, no changes were made to the Repur…